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Abstract
 
Adoptive transfer of cross-reactive HSP60-specific CD8
 
 
 
 T cells into immunodeficient mice
causes autoimmune intestinal pathology restricted to the small intestine. We wondered
whether local immunopathology induced by CD8
 
 
 
 T cells can be explained by tissue-specific
differences in proteasome-mediated processing of major histocompatibility complex class I T
cell epitopes. Our experiments demonstrate that 20S proteasomes of different organs display a
characteristic composition of 
 
 
 
 and 
 
 
 
 chain subunits and produce distinct peptide fragments
with respect to both quality and quantity. Digests of HSP60 polypeptides by 20S proteasomes
show most efficient generation of the pathology related CD8
 
 
 
 T cell epitope in the small intes-
tine. Further, we demonstrate that the organ-specific potential to produce defined T cell
epitopes reflects quantities that are relevant for cytotoxic T lymphocyte recognition. We pro-
pose tissue-specific antigen processing by 20S proteasomes as a potential mechanism to control
organ-specific immune responses.
 
Key words: antigen processing • proteasomes • intestinal mucosa • T cell epitopes • autoimmunity
 
Introduction
 
Understanding of organ-specific autoimmune diseases is
hampered by a dilemma: although some autoantigens are
 
ubiquitously expressed, they provoke local pathogenic
immune responses (1, 2). A healthy organism presents au-
tologous peptides which are normally tolerated or ignored
by peripheral T lymphocytes. Microbial infections, muta-
tions of cellular proteins or failure in immunoregulation can
 
activate CD8
 
 
 
 T cells causing organ-specific autoimmune
pathology. We have established mycobacterial HSP60-spe-
cific CD8
 
 
 
 T cells that cross react with the murine homo-
 
logue. HSP60 peptides of either mycobacterial (AA
 
499–508
 
:
SALQNAASIA) or murine origin (AA
 
162–171
 
: KDIGNI-
ISDA) are recognized in a H-2D
 
b
 
–restricted fashion (3).
While these cross-reactive T cells did not cause pathology
in immunocompetent mice, adoptive transfer into immuno-
deficient mice resulted in organ-specific inflammation of
the small intestine but not the colon, despite comparable
migration in both tissues, and elevated expression of murine
 
heat shock protein 60 (mu HSP60)
 
*
 
 in the colon (2). We
therefore wondered whether different tissues exhibit differ-
ences in their capacity to process MHC class I antigens.
MHC class I molecules are ubiquitously expressed sur-
face molecules which bind peptides of 8–10 amino acids for
display to the T cell system. These peptides are antigenic
side products in the continual turnover of intracellular pro-
teins, mostly originating from ubiquitin-tagged proteins
(4). Most of these peptides are generated by 26S protea-
somes, the major proteolytic enzyme machinery of a cell
(5, 6). Although other proteases with selective cleavage
specificity might also contribute to the MHC class I pep-
tide pool, this seems to apply only for a limited subset of
peptides and cannot substitute for proteasome function (7).
The proteolytic active sites of the 26S proteasomes are
housed within the 20S core complex that is composed of
four stacked rings with seven subunits each. The outer
rings contain the 
 
 
 
-subunits (
 
 
 
1–
 
 
 
7) which shape the gates
of substrate entry and product release. The two inner rings
harbor the 
 
 
 
 subunits (
 
 
 
1–
 
 
 
7) of which three 
 
 
 
-subunits,
 
 
 
1, 
 
 
 
5, and 
 
 
 
2 are catalytically active (8). Stimulation with
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IFN-
 
 
 
 results in an exchange of these constitutive 
 
 
 
 sub-
units with the inducible i
 
 
 
1 (LMP2), i
 
 
 
5 (LMP7), and i
 
 
 
2
(MECL-1) subunits leading to the formation of immuno-
proteasomes (9–11). Cytokine-induced subunit exchange
occurs during proteasome assembly and profoundly alters
the cleavage specificity of 20S proteasomes (12, 13).
To investigate whether tissue-restricted pathology is influ-
enced by organ-specific processing of MHC class I ligands,
we analyzed the subunit composition of 20S proteasomes
from various organs and compared their ability to generate
peptides and T cell epitopes which are involved in the in-
duction of organ-specific pathology of the small intestine.
 
Materials and Methods
 
Mice.
 
Mice were bred in the animal facilities of the Max-
Planck Institute at the Bundesamt für gesundheitlichen Ver-
braucherschutz und Veterinärmedizin (BgVV) under specific
pathogen-free conditions.
 
Proteasome Purification.
 
20S proteasomes were isolated from
the liver, small intestine, colon, spleen, and thymus of normal
C57BL/6 mice. These mice were chosen because 20S protea-
somes subunit composition did not differ from 
 
 
 
/
 
 
 
 T cell–defi-
cient (
 
 
 
 TCR
 
 
 
/
 
 
 
) mice, which develop pathology (2). Organs
were carefully rinsed and frozen in liquid nitrogen. The tissues
were homogenized in 5 to 10 volumes of lysis buffer containing
20 mM Tris, pH 7.2, 1 mM EDTA, 1 mM NaN
 
3
 
, 1 mM DTT,
50 mM NaCl, 0.1% NP-40 supplemented with 4 mM PMSF, 2
 
 
 
M Pepstatin, 2 
 
 
 
M Leupeptin, 0.6 
 
 
 
M Aprotinin, 13 
 
 
 
M Be-
statin, 10 and 100 
 
 
 
g/ml trypsin inhibitor (fourfold higher con-
centrations of PMSF and trypsin inhibitor were used for lysis of
small intestines). Filtered lysates were applied onto DEAE
Sephacel (Amersham Pharmacia Biotech) and carefully washed
with 50 and 150 mM NaCl until no protein was detected by UV
absorption (280 nm). Proteasomes were eluted with 350 mM
NaCl in TEAD (20 mM Tris, pH 7.2, 1 mM DTT) buffer and
concentrated by ammonium sulfate precipitation between 40 to
70% saturation. Protein fractions were separated by ultra centrifu-
gation on sucrose gradients (10 to 40%) and ultracentrifuged at
40,000 rpm for 16 h in a Beckman Coulter SW40 rotor. Frac-
tions containing proteasomes were pooled and applied to a
MonoQ
 
®
 
 column (FPLC Pharmacia) and eluted with a linear
gradient of 100 to 500 mM NaCl in TEAD. The reproducibility
of the 20S proteasome purification and the 2D-gel protein pat-
tern was confirmed by four independent experiments.
 
Protease Assay.
 
The proteolytic activity of the proteasomes
was tested with the synthetic peptide substrate Suc-LLVY-MCA.
The assay was performed in a 100 
 
 
 
l reaction volume containing
100 ng proteasome, 50 mM Tris/Cl, pH 7.5, 10 mM NaCl, 30
mM KCl, 0.1 mM EDTA, and 20 
 
 
 
M substrate. Fluorescence
was detected by fluorescence microtiter reader Fluostar
(TECAN
 
®
 
) at 390 nm excitation/460 nm emission for MCA.
 
Peptide Digest.
 
To determine 20S proteasome mediated
cleavage of synthetic peptides, 20 
 
 
 
g of a 30 mer peptide derived
from the mu HSP60 (VATISANGDKDIGNIISDAMKKVGR-
KGVIT) were incubated at 37
 
 
 
C for 1 to 20 h with 2 
 
 
 
g of the
purified 20S proteasomes in buffer containing 20 mM Hepes/
KOH, pH 7.8; 2 mM Mg-acetate; 2 mM DTT in a total volume
of 300 
 
 
 
l. Reactions were stopped by adding TFA to a final con-
centration of 0.1% or by freezing at –70
 
 
 
C.
 
Peptide Analysis and Quantification.
 
Samples were analyzed by
reverse phase HPLC (RP-HPLC), system HP1100 (Hewlett-
 
Packard) equipped with a RPC C2/C18 SC 2.1/10 column
(Amersham Pharmacia Biotech). A gradient of eluent A (0.05%
TFA) and eluent B (80% acetonitrile, 0.05% TFA) between
5–63% B was run in 30 min, followed by 63–95% B in 4 min;
with a flow rate of 50 
 
 
 
l/min. Analysis was performed on-line
with a LCQ ion trap MS (ThermoQuest) equipped with an elec-
trospray ion source. Each scan was acquired over the range 
 
m/z
 
300–1300 in 3 s. Peptides were identified by their molecular
masses calculated from the m/z peaks of the single or multiple
charged ions and were confirmed by tandem mass spectrometry
(MS) sequencing analyses. The strongest electric signal induced
by an individual peptide generated by organ derived 20S protea-
somes was defined as 1.
 
Two-Dimensional Gelelectrophoresis and Spot Identification by MS.
 
For resolution of 20S proteasomal proteins, we combined isoelec-
tric focusing by carrier ampholytes with SDS-PAGE (14). We ap-
plied 60 
 
 
 
g of protein to the anodic side of a carrier ampholyte
IEF gel. In the second dimension, proteins were separated in 1.5
mm thick SDS-PAGE gels (23 cm 
 
 
 
 30 cm) and stained by Coo-
massie Brilliant Blue G250. For identification, individual spots
were cut out, digested by trypsin, desalted and concentrated
by ZIPTIP, and analyzed by matrix-assisted laser desorption-
ionization mass spectrometry (MALDI-MS) as recently de-
scribed (15).
 
51
 
Cr-release Assay.
 
CTL activities of HSP60-specific T cells
were measured in a 
 
51
 
Cr release assay using EL4 cells as targets as
described previously (3). Cloned T cells were incubated with 2 
 
 
 
10
 
3
 
 
 
51
 
Cr-labeled EL4 cells in the presence of 20 
 
 
 
l HSP60 sub-
strate digests by 20S proteasomes from various organs for 4 h at
37
 
 
 
C in 7% CO
 
2
 
 at various effector/target ratios. After 4 h, 100
 
 
 
l of the supernatant was removed and measured in a gamma
counter. Percent specific lysis was calculated as follows: (experi-
mental 
 
51
 
Cr-release 
 
 
 
 spontaneous 
 
51
 
Cr-release) 
 
 
 
 100/(maxi-
mum 
 
51
 
Cr-release 
 
  
 
spontaneous 
 
51
 
Cr-release).
 
Histology.
 
Examination of histopathology was performed
with tissues from naive and T cell reconstituted mice. Tissues
were fixed in 4% PFA, dehydrated in cold acetone, and embed-
ded into Kulzer Technovit 8100 (Haereus Kulzer) following the
manufacturer’s instructions. After polymerization, sections were
cut at 3 
 
 
 
m on a rotation microtome (Leica) and stained with he-
matoxylin and eosin. Tissues were graded in a blinded fashion
from a pathologist according to signs of T cell infiltrations, mucosa
thickening, hemorrhage, and epithelial cell integrity. Immunohis-
tochemistry was performed on cryostat sections that have been
blocked with PBS containing 5% mouse serum and then incu-
bated with the primary antibody (anti-V
 
 
 
8.1, 8.2-FITC) for 60
min. Secondary Ab incubation was performed with rat anti-FITC
peroxidase-conjugated mAb (Boehringer). Endogenous peroxi-
dase was blocked with 3% H
 
2
 
0
 
2
 
 for 2 min, and staining was visu-
alized by addition of 3-amino-9-ethylcarbazole (Dakopatts) as
substrate. Phosphate-buffered saline was used for washing steps
between the antibody incubations. Specificity of staining was
checked with isotype-matched control mAbs.
 
Results and Discussion
 
Subunit Composition of 20S Proteasomes from Various Tis-
sues.
 
To determine whether the composition of the 20S
core proteasomes differs between various tissues, we iso-
lated 20S proteasomes from liver, thymus, small intestine,
and colon by two-dimensional gelelectrophoresis (2-DE)
and identified proteins by MALDI-MS. Marked differences 
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between individual organs were observed including both
 
 
 
-subunits as well as 
 
 
 
-subunits of the 20S proteasome
(Fig.1, A–D). Focusing specifically on the model of the in-
testinal autoimmune pathology, a detailed MALDI-MS
analysis of the 20S proteasome subunits from the small in-
testine and the colon were performed. The results of this
analysis are listed in Table I. In the small intestine, the 
 
 
 
4
subunit was identified in three spots (
 
 
 
4.1–
 
 
 
4.3) showing
similar molecular mass (Mr) but different isoelectric points
(pI), suggesting posttranslational modifications as a cause for
this polymorphism. While these variant forms were present
with similar intensities in the colon, the 
 
 
 
4.2 and 
 
 
 
4.3
were markedly reduced in the small intestine. The 
 
 
 
6 sub-
unit was detected in three spots which differed not only in
the pI but also in their relative Mr. In the small intestine,
the 
 
 
 
6 variants were present in equimolar ratios, whereas
in the colon the 
 
 
 
6.1 dominated over the 
 
 
 
6.2 and 
 
 
 
6.3
variants which were only marginally present, comparable to
the liver (Fig. 1, A–D). These polymorphisms in the sub-
unit composition of 20S proteasomes may be due to tissue
specific functional modifications, including differential tran-
scription and posttranslational modification as has been dis-
cussed previously (16–18).
Notably, the 
 
 
 
4 and 
 
 
 
6 subunits are known to interact
with the proteasomal regulatory complexes PA700 and
PA28 and additional proteins of cellular and viral origin
(19, 20). It is therefore assumed that protein interactions
with the 
 
 
 
4 and 
 
 6 subunits may modulate the activity of
the 20S proteasome by controlling substrate entry into the
catalytic cavity (21).
The proteasomes of different tissues also revealed a char-
acteristic composition of  -subunits. The immunoprotea-
some subunits i 1, i 2, and i 5 were predominantly found
in the small intestine and the thymus, whereas high
amounts of the constitutive proteasome subunits  1,  2,
and  5 were detected in proteasomes of the colon and the
liver. However, most prominent differences were observed
for the  2 subunit which varied with respect to the pI and
size between the organs analyzed. While the ratio of  2
and i 2 expression was similar in the colon and in the liver,
increased amounts of the i 2 subunit and lowered level of
 2 was observed in the thymus and the small intestine. In-
terestingly, the subunits of the latter organs focused at a
more basic pI (Fig. 1, A–D, right panel). The molecular ba-
sis of this shift is not yet clear.
Generation of HSP60 Cleavage Fragments and T Cell
Epitopes. To examine the potential consequences of or-
gan-specific proteasome subunit composition, we first
compared the generation of distinct cleavage fragments of
the mu HSP60 substrate by organ-derived 20S protea-
Figure 1. The subunit composi-
tion of 20S proteasomes varies be-
tween different organs. Purified 20S
proteasomes were analyzed by 2-DE
and MS identified spots of the thy-
mus, small intestine, and colon were
compared with proteasomes subunits
of the liver. Identification of the main
subunits in the liver (A). Differences
in   subunits of thymus (B), small
intestine (C), and colon (D) were
marked by black triangles. The  
immunosubunits (i ) and the corre-
sponding constitutive subunits ( )
are indicated. The right panel de-
picts an enlarged view of the indi-
cated area in the 2-DE. Note that
 2 and i 2 subunits differ in their
relative Mr and pI. To ensure repro-
ducibility, four individual prepara-
tions of 20S proteasomes were per-
formed for each organ.986 Organ-specific Antigen Processing by 20S Proteasomes
somes. Therefore, 20S proteasomes isolated from various
tissues were normalized according to their protein amount
since the adjustment of tissue derived 20S proteasomes
based on their hydrolytic activity against short fluorogenic
peptide substrates strongly depends on the content of im-
munosubunits (22). The purity of 20S proteasomes was as-
sessed by native PAGE followed by fluorogenic substrates
overlay, which excludes the copurification of contaminat-
ing proteases. Sequence information of cleavage products
was obtained by tandem MS. The main cleavage products
of the mu HSP60 from tissue derived proteasomes are sum-
marized in Table II. Although there were few qualitative
Table I. Subunit Differences of 20S Proteasomes from the Small Intestine and Colon
 -Subunits Gene Spot Small intestine Colon
 1 (Jota) PSMA 6  1   
 2 (C3) PSMA 2  2   
 3 (C9) PSMA 4  3.1/ 3/2   
 4 (C6) PSMA 7  4.1
 4.2
 4.3  4.1    4.2    4.3  4.1    4.2    4.3
 5 (Zeta) PSMA 5  5   
 6 (C2) PSMA 1  6.1
 6.2
 6.3  6.3    6.2    6.1  6.1    6.2    6.3
 7 (C8) PSMA 3  7   
 -Subunits
 1 (delta) PSMB 6  1     
i 1 (LMP2) PSMB 9 i 1    ( )
 2 (Z) PSMB 7  2 (anodic)
 2 (cathodic)
 
  
  
( )
i 2 (MECL1) PSMB 10 i 2 (anodic)
i 2 (cathodic)
 
  
 
( )
 3 (C10) PSMB 3  3   
 4 (C7) PSMB 2  4   
 5 (MB1) PSMB 5  5(  )   
i 5 (LMP7) PSMB 8 i 5    ( )
 6 (C5) PSMB 1  6   
 7 (N3) PSMB 4  7   
 - and  -subunits of 20S proteasomes isolated from small intestines and colons were compared and evaluated:   comparable amounts; ( ) traces;  
not detectable;   normal intensity;    increased intensity.  2 and i 2 were detected in two isoforms differing in their IP (anionic and cathodic,
respectively). The basic isoforms of  2 and i 2 were strongly expressed in the small intestine and only marginally in the colon and thymus.987 Kuckelkorn et al.
differences in cleavage products, some tissues varied mark-
edly in the quantity of peptides generated. The quantitative
assignment of peptides to individual organs shows, that the
majority of fragments were most efficiently produced by
tissues expressing high levels of immunosubunits, i.e., the
small intestine and thymus. However, despite the fact that
the small intestine and the thymus express comparable lev-
els of immunoproteasomes, they differed significantly in
their cleavage site preferences. As proteasomes of the small
intestine and the thymus differed only in their  -subunit
composition as described in Table I, these data indicate that
modifications in the  -subunits of 20S proteasomes may
also influence their processing characteristics.
With respect to the localized inflammation mediated by
HSP60-specific T cells, we next analyzed the ability of 20S
proteasomes from various tissues to generate epitopes of the
mu HSP60 polypeptide substrate. Although one can as-
sume that in vivo most of the antigens are processed by the
26S proteasomes it has been demonstrated for a large num-
ber of viral and tumor antigens that in vitro processing of
polypeptide substrates containing MHC class I epitopes by
20S proteasomes closely resembles the situation in living
cells (for a review, see reference 23). Nevertheless, as in
vitro data suggested differences in the generation of cleav-
age fragments between 20S and 26S proteasomes (24), we
investigated whether both types of proteasomes were able
to generate the mu HSP60 T cell epitope. MS analyses re-
vealed generation of the pathology relevant epitope by the
20S as well as the 26S proteasomes supporting the rele-
vance of the data obtained with purified 20S proteasomes
(data not shown). Fig. 2 summarizes the relative abundance
of T cell epitopes produced by organ derived 20S protea-
somes. The mu HSP60 T cell epitope KDIGNIISD and
NH2-terminally elongated fragments which could serve as
precursors were generated in a significantly more efficient
way by the small intestine compared with the colon. Simi-
lar results demonstrating organ-specific preferences in
cleavage site usage were also obtained with a polypeptide
substrate derived from the pp89 protein of the murine cy-
tomegalovirus (data not shown).
Recognition of In Vitro Generated Epitopes by HSP60-specific
CTLs Correlates with the Intestinal Pathology of T Cell Recon-
stituted   TCR /  Mice. To show that peptides were ex-
clusively processed by 20S proteasomes and not by con-
taminating cytosolic proteases, in vitro digests of the mu
HSP60 were performed in the presence of the proteasome
inhibitor MG 132 or an inhibitor of the cytosolic tripepti-
dyl peptidases II, AAF-CMK. The HPLC-profiles reveal
that peptide fragmentation of the mu HSP60 substrate was
mediated by 20S proteasomes and not by contaminating
proteases (Fig. 3 A).
We next investigated whether in vitro–generated epi-
topes were of functionally relevant amounts and quality.
To this end, recognition of HSP60 digests was determined
in a 51Cr release assay. Studies with overlapping peptides
revealed that the epitopes KDIGNIISDA and KDIGNIISD
of the mu HSP60 were recognized by T cells at physiolog-
ical concentrations of 10 10 M (3). Target cells pulsed with
cleavage products derived from 20S proteasomes of the
small intestine but not from other organs were lysed by
HSP60-specific T cells (Fig. 3 B). Specific recognition of
the mu HSP 60 T cell epitope in the small intestine but not
the colon is in accordance with the pathology observed in
HSP60 T cell–reconstituted   TCR /  mice. Cross sec-
tions of the small intestines revealed hemorrhage and im-
mense expansion of HSP60-specific T cells in the lamina
Table II. Proteasomal Cleavage Products (Differ between Organs)
Cleavage products
1  5 1 0 1 5 2 02 53 0 Organs
VATISANGDKDIGNIISDAMKKVGRKGVIT SI C L SP T
VATIS 0.7 0.2 0.5 0.5 1.0
VATISA 1.0 0.3 1.0 0.5 0.9
VATISANGD 0.8 0.2 0.5 0.6 1.0
SANGDKDIGNIISD 1.0 0.1 0.1 0.2 0.5
NGDKDIGNIISDAMKKVGRKGVIT 1.0 0.3 0.8 0.4 0.9
KDIGNIISD 1.0 0.1 0.2 0.1 0.5
KVGRKGVIT 0.7 0.6 0.2 1.0 0.9
VGRKGVIT 1.0 0.8 0.1 0.1 0.1
KGVIT 0.6 1.0 0.1 0.1 0.1
The mu HSP60 substrate (VATISANGDKDIGNIISDAMKKVGRK-
GVIT) was digested by isolated 20S proteasomes from various organs
(SI, small intestine; C, colon; L, liver; SP, spleen and T, thymus).
Peptide sequences were analyzed by MS, maximal signal intensities of
individual peptides were arbitrarily defined as 1.0. Main cleavage
products of the mu HSP60 substrate are listed and the relative amounts
generated by individual organs are shown to the right.
Figure 2. Generation of organ-specific peptide fragments by 20S pro-
teasomes. The mu HSP60 substrate (VATISANGDKDIGNIIS-
DAMKKVGRKGVIT) was digested by isolated 20S proteasomes from
various organs (SI, small intestine; C, colon; L, liver; SP, spleen and T,
thymus). Peptide sequences were analyzed by MS, maximal signal intensi-
ties of individual peptides were arbitrarily defined as 1.0. Relative
amounts of a potential precursor (5–18) and the T cell epitope (10–18) of
the mu HSP60. Data from three experiments, means   SD are shown.988 Organ-specific Antigen Processing by 20S Proteasomes
propria and epithelium leading to the destruction of the
apical epithelial barrier (Fig. 4 C). In contrast, despite the
fact that HSP60-specific T cells were also found in the co-
lon, immunopathology did not develop in this tissue (Fig.
4, D–F).
Mammalian proteasomes generate with high accuracy
the COOH-terminal residues of MHC class I peptides. Of-
ten, however, antigenic peptides are not generated as 8 or
10-residue products but as NH2-terminal extended precur-
sor peptides that require trimming by amino peptidases (25,
26). Most of these enzymes are located in the endoplasmic
reticulum, but in some rare cases cytosolic trimming has
also been described. In addition, there is convincing evi-
dence that proteasomes cleave some MHC class I ligands in
a definite form (27). This is in accordance with our data
showing that isolated 20S proteasomes are sufficient to
cleave the T cell epitope of muHSP 60 (KDIGNIISD) at
both ends, although we cannot exclude that trimming of
the proteasomal precursor epitope, SANGDKDIGNIISD,
also leads to the maturation of the T cell epitope.
Recently, it has been shown that muscle cells contain
several 20S proteasomes subtypes which exhibit different
cleavage properties. Although the biological significance of
this observation remains at present unclear and requires
further studies, it can be concluded that the cleavage prop-
erties of cells or organs most likely reflect the sum of dif-
ferent subtype activities (28). Notably, tissues (thymus,
small intestine) having comparable levels of immunosub-
units varied considerably in their cleavage preference. This
indicates that the preferred cleavage site usage of 20S pro-
teasomes is also influenced by isoforms of   subunits
present in the organ.
Although we would like to attribute the recorded func-
tional and structural proteasome differences to individual
cell types, such experiments are currently not possible due
to technical limitations. Further, isolating individual cell
types from their normal microenvironment does not reflect
the processing and presentation pattern of cells which re-
side in their physiological environment. This has recently
been demonstrated by differences in antigen presentation
between infected splenocytes and macrophages (29).
Our data demonstrate that 20S proteasomes are sufficient
to generate the CD8  T cell epitopes of the mu HSP60 and
that 20S proteasomes derived from different organs produce
a distinct peptide pattern due to their organ-typic subunit
composition. Therefore, generation of high quantities of
self-epitopes in selected tissues may correlate with organ-
specific autoimmunity. Thus, we propose that in addition to
peripheral immune regulatory mechanisms, organ-specific
epitope generation represents an important mechanism to
control the reactivity of autoreactive CD8  T cells that es-
cape thymic deletion. In the absence of peripheral immune
regulation, processing of self-epitopes in distinct tissues may
result in organ-specific pathology. This raises the general
concept that proteasomal antigen processing is a further step
in the control of organ-specific immune responses caused by
CD8  T cells ranging from pathology to protection.
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Figure 3. HSP60-specific T cells recognize peptides generated by 20S proteasomes from the small intestine. (A) HPLC profiles of a 30 mer peptide of
HSP60 before digestion (HSP60, 0 h), after proteasomal digestion for 20 h (HSP60, 20h), after proteasomal digestion for 20 h in the presence of 3  M
tripeptidyl peptidase inhibitor AAF-CMK (HSP60, 20h   AAF-CMK) and the proteasomes inhibitor MG 132 (HSP60, 20h   MG 132), respectively.
(B) Cytolytic activity of a cross-reactive HSP60-specific T cell clone was measured in a 51Cr-release assay on EL-4 cells loaded with equal amounts of di-
gests (20  l) of HSP60 performed by 20S proteasomes from the small intestine ( ), the liver ( ), the colon ( ), the thymus ( ) or left untreated ( ).
EL-4 cells were loaded with digests performed by small intestinal 20S proteasomes in the presence of 3  M proteasome inhibitor MG132 ( ).989 Kuckelkorn et al.
Figure 4. Transfer of HSP60-specific T cells
into   TCR /  mice leads to inflammation of the
small intestine but not the colon. Hematoxylin
and eosin stained cross sections of the naive small
intestine (A) and the colon (B) and 16 d after re-
constitution with HSP60-specific T cells, small
intestine (C), colon (D). Cross sections of the
small intestine (C) but not the colon (D) show
massive expansion of HSP60-specific T cells in
the lamina propria and epithelium with degenera-
tive processes at the apical end of the villi.
HSP60-specific T cells were detected 16 d after
adoptive transfers in the colon by staining for
V 8.1/V 8.2 positive lymphocytes, overview
(E), and detailed section (F).990 Organ-specific Antigen Processing by 20S Proteasomes
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